Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. The aim of this study was to analyse the antifibrotic effects of nintedanib in preclinical models of systemic sclerosis (SSc) and to provide a scientific background for clinical trials in SSc. Methods The effects of nintedanib on migration, proliferation, myofibroblast differentiation and release of extracellular matrix of dermal fibroblasts were analysed by microtitre tetrazolium and scratch assays, stress fibre staining, qPCR and SirCol assays. The antifibrotic effects of nintedanib were evaluated in bleomycin-induced skin fibrosis, in a murine sclerodermatous chronic graft-versus-host disease model and in tight-skin-1 mice. Results Nintedanib dose-dependently reduced platelet-derived growth factor-induced and transforming growth factor-β-induced proliferation and migration as well as myofibroblast differentiation and collagen release of dermal fibroblasts from patients with and healthy individuals. Nintedanib also inhibited the endogenous activation of SSc fibroblasts. Nintedanib prevented bleomycin-induced skin fibrosis in a dose-dependent manner and was also effective in the treatment of established fibrosis. Moreover, treatment with nintedanib ameliorated fibrosis in the chronic graft-versus-host disease model and in tight-skin-1 mice in well-tolerated doses. Conclusions We demonstrate that nintedanib effectively inhibits the endogenous as well as cytokine-induced activation of SSc fibroblasts and exerts potent antifibrotic effects in different complementary mouse models of SSc. These data have direct translational implications for clinical trials with nintedanib in SSc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, it lowers the myofibroblasts count and skin fibrosis in bleomycin induced skin fibrosis in mice (197).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [197]
In the citing paper
“In SSc skin fibroblasts, nintedanib also prevents proliferation and motility and lowers the expression of αSMA (197).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [197]
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,886
Self-citationTyndall, A. J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P. E., Bancel, D. F., Allanore, Y., Müller-Ladner, U., Distler, O., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114264 · Cited by 1,443
Self-citationGabrielli, A., Avvedimento, E. V., & Krieg, T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0806188 · Cited by 1,384
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
Akhmetshina, A., Palumbo, K., Dees, C., Bergmann, C., Venalis, P., Zerr, P., Horn, A., Kireva, T., Beyer, C., Zwerina, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms1734 · Cited by 843
Self-citationWollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Self-citationAngiogenic and angiostatic factors in the molecular control of angiogenesis.
Distler, J. H. W., Hirth, A., Kurowska‐Stolarska, M., Gay, R. E., Gay, S., & Distler, O. (2003) · PubMed · Cited by 398
Self-citationDistler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
Self-citationOrphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
Palumbo-Zerr, K., Zerr, P., Distler, A., Fliehr, J., Mancuso, R., Huang, J., Mielenz, D., Tomcik, M., Fürnrohr, B. G., Scholtysek, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3777 · Cited by 342
Self-citation
Cited by
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationSystemic sclerosis-associated interstitial lung disease
Perelas, A., Silver, R. M., Arrossi, A. V., & Highland, K. B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30480-1 · Cited by 422
Fibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Self-citationExploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis
Tashiro, J., Rubio, G. A., Limper, A. H., Williams, K., Elliot, S. J., Ninou, I., Aidinis, V., Tzouvelekis, A., & Glassberg, M. K. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00118 · Cited by 314
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Wollin, L., Distler, J. H. W., Redente, E. F., Riches, D. W. H., Stowasser, S., Schlenker-Herceg, R., Maher, T. M., & Kolb, M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00161-2019 · Cited by 296
Self-citation
Metadata
- Authors
- Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., & Distler, J. H. W.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University Hospital Zurich (CH)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Distler, Jörg H W
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 75
- Issue
- 5
- Pages
- 883-890
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2159148154
- Cited by
- 196
- References
- 42
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 12 · 2023: 12 · 2022: 15 · 2021: 27 · 2020: 25 · 2019: 28 · 2018: 17 · 2017: 21 · 2016: 12
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- nintedanib, systemic sclerosis, fibroblast activation, antifibrotic therapy, myofibroblast differentiation, dermal fibroblasts, bleomycin-induced skin fibrosis, chronic graft-versus-host disease, platelet-derived growth factor, TGF-beta, collagen deposition, tyrosine kinase inhibitors
- MeSH terms
- Animals, Bleomycin, Cell Movement, Cells, Cultured, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Female, Fibroblasts, Fibrosis, Graft vs Host Disease, Humans, Indoles, Male, Mice, Inbred BALB C, Mice, Mutant Strains, Scleroderma, Systemic, Skin, Protein Kinase Inhibitors, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-207109
- The paper
- Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., & Distler, J. H. W. (2016). Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-207109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.